Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JNJ-90189892
- Development stage
- Phase 1
- Lead developer
- Janssen Research & Development
01
Overview
JNJ-90189892 is an investigational antineoplastic drug being developed by Janssen Research & Development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (MDS). It is a new molecular entity currently in Phase 1 clinical trials, with its mechanism of action not yet publicly disclosed. The drug is being evaluated in a first-in-human, dose-escalation study to determine safety, tolerability, and preliminary efficacy in patients who have failed prior therapies. The specific modality and molecular target remain undisclosed as of the latest updates[3][7][9].
- Other names
- JNJ 90189892JNJ90189892JNJ-90189892
Beyond the preview
Go deeper on JNJ-90189892.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JNJ-90189892.